TY - JOUR T1 - Recurrence of primary disease following lung transplantation JF - ERJ Open Research JO - erjor DO - 10.1183/23120541.00038-2022 SP - 00038-2022 AU - Dorina Rama Esendagli AU - Prince Ntiamoah AU - Elif Kupeli AU - Abhishek Bhardwaj AU - Subha Ghosh AU - Sanjay Mukhopadhyay AU - Atul C. Mehta Y1 - 2022/01/01 UR - http://openres.ersjournals.com/content/early/2022/04/07/23120541.00038-2022.abstract N2 - Lung transplant has become definitive treatment for patients with several end-stage lung diseases. Since the first attempted lung transplantation in 1963, survival has significantly improved due to advancement in immunosuppression, organ procurement, ex-vivo lung perfusion, surgical techniques, prevention of chronic lung allograft dysfunction, and bridging to transplant using extra-corporeal membrane oxygenation. Despite a steady increase in number of lung transplantations each year, there is still a huge gap between demand and supply of organs available, and work continues to select recipients with potential for best outcomes. According to review of the literature, there are some rare primary diseases that may recur following transplantation. As the number of lung transplants increase, we continue to identify disease processes at highest risk for recurrence, thus shaping our future approaches. While the aim of lung transplantation is improving survival and quality of life, choosing the best recipients is crucial due to shortage of donated organs. Here we discuss the common disease processes that recur and highlight its impact on overall outcome following lung transplantation.FootnotesThis manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article. ER -